Workshop on In Vitro to In Vivo Extrapolation
In Vitro to In Vivo Extrapolation for High Throughput Prioritization and Decision Making
February 17-18, 2016
U.S. Environmental Protection Agency
Research Triangle Park, North Carolina, USA
Data from high throughput in vitro tests are being generated for many chemicals of environmental and commercial interest, with the expectation that in vitro assay data could ultimately be used to predict adverse effects of chemical exposures in vivo. Translating values obtained from in vitro assays into estimates of in vivo outcomes is a complex process involving the use of mathematical modeling and increasingly complex test systems. This series of four webinars culminating in an in-person workshop addressed the capabilities and the limitations of in vitro to in vivo extrapolation (IVIVE) within the context of risk decision making.
During the workshop participants (1) reviewed the state of the science to form recommendations on the best practices for using IVIVE in chemical screening and risk decision making, (2) identified areas that require additional data and/or research, and (3) highlighted examples of how best to apply IVIVE in a tiered risk decision-making strategy.
The workshop built on information presented in an October 2015-January 2016 webinar series. Slides from the webinars are available below under "Webinar Materials."
Warren Casey, NIEHS/NICEATM
The EURL ECVAM Toxicokinetics Report and EURL ECVAM Strategy
Alicia Paini, EURL ECVAM
Workshop Background and Summaries of Webinars
John Wambaugh, EPA
Session 1: Application in Risk Assessment: What Do We Need for Decision-making and Prioritization?
Using In Vitro Data in Quantitative Risk Assessments (QRAs)
Paul Price, EPA
Quantitative Considerations of Dose-Response for IVIVE
Ted Simon, Ted Simon LLC
Toxicokinetics in Risk Assessment: From Predictive Evaluations to Regulatory Testing
Mike Bartels, The Dow Chemical Company
Development and Application of Biologically Based Dose-Response Modeling for Pregnancy Conditions: Evaluation of Thyroid Active Chemical Exposure During Sensitive Life Stages
Annie Lumen, U.S. Food and Drug Administration
Session 2: Metabolism and Excretion
Strength and Limitations of In Vitro Xenobiotic Metabolism Assays and In Silico Models
Stephen Ferguson, NIEHS
In Silico Screening of Primary Clearance Mechanisms
John Troutman, The Procter & Gamble Company
In Vitro Models for Quantitative Prediction of Hepatobiliary Clearance
Kim Brouwer, University of North Carolina at Chapel Hill
Session 3: In Silico Modeling
Predictive Power of PBPK Modeling and In Silico/In Vitro-In Vivo Extrapolation Using GastroPlus™ and ADMET Predictor™ Software Tools
Grazyna Fraczkiewicz, Simulations Plus, Inc.
In Vitro In Vivo Extrapolation and its Applications in Predicting Pharmacokinetic Population Variability
Alice Ke, SimCyp, a Certara Company
October 7: Setting the Stage: Purpose, Definitions, Scope, and Assumptions
Barbara Wetmore, Ph.D., The Hamner Institutes for Health Sciences
November 4: Building Fit-for-purpose Pharmacokinetic Models
John Wambaugh, Ph.D., National Center for Computational Toxicology, EPA
December 3: The Role of Pharmacokinetic Model Evaluation
Lisa Sweeney, Ph.D., Naval Medical Research Unit Dayton and Jackson Foundation for the Advancement of Military Medicine